These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31035335)

  • 1. Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen.
    Štambuk N; Konjevoda P; Turčić P; Šošić H; Aralica G; Babić D; Seiwerth S; Kaštelan Ž; Kujundžić RN; Wardega P; Žutelija JB; Gračanin AG; Gabričević M
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
    Correale P; Walmsley K; Nieroda C; Zaremba S; Zhu M; Schlom J; Tsang KY
    J Natl Cancer Inst; 1997 Feb; 89(4):293-300. PubMed ID: 9048833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple three-step method for design and affinity testing of new antisense peptides: an example of erythropoietin.
    Štambuk N; Manojlović Z; Turčić P; Martinić R; Konjevoda P; Weitner T; Wardega P; Gabričević M
    Int J Mol Sci; 2014 May; 15(6):9209-23. PubMed ID: 24865486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer.
    Alexander RB; Brady F; Leffell MS; Tsai V; Celis E
    Urology; 1998 Jan; 51(1):150-7. PubMed ID: 9457311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a prostate carcinoma mucin-like antigen (PMA).
    Beckett ML; Wright GL
    Int J Cancer; 1995 Sep; 62(6):703-10. PubMed ID: 7558418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of PSA peptide mimotopes using phage display peptide library.
    Shanmugam A; Suriano R; Chaudhuri D; Rajoria S; George A; Mittelman A; Tiwari RK
    Peptides; 2011 Jun; 32(6):1097-102. PubMed ID: 21539876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope mapping of prostate-specific antigen with monoclonal antibodies.
    Jette DC; Kreutz FT; Malcolm BA; Wishart DS; Noujaim AA; Suresh MR
    Clin Chem; 1996 Dec; 42(12):1961-9. PubMed ID: 8969633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technical variations in prostatic immunohistochemistry: need for standardisation and stringent quality assurance in PSA and PSAP immunostaining.
    Varma M; Berney DM; Jasani B; Rhodes A
    J Clin Pathol; 2004 Jul; 57(7):687-90. PubMed ID: 15220358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.
    Mikolajczyk SD; Marker KM; Millar LS; Kumar A; Saedi MS; Payne JK; Evans CL; Gasior CL; Linton HJ; Carpenter P; Rittenhouse HG
    Cancer Res; 2001 Sep; 61(18):6958-63. PubMed ID: 11559576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further investigation of the epitope recognized by the new monoclonal antibody 2C9.
    Kato K; Yoshikawa K; Taki T; Shitara K; Nakamura K; Hirota M; Hanai N; Nakamura K; Kokubo H; Mitsui K; Yamada Y; Honda N; Ueda R; Saga S; Fukatsu H
    Int J Urol; 2003 Aug; 10(8):439-44. PubMed ID: 12887366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen.
    Leinonen J; Wu P; Koivunen E; Närvänen A; Stenman UH
    Scand J Clin Lab Invest Suppl; 2000; 233():59-64. PubMed ID: 11317943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope mapping of antibodies against prostate-specific antigen with use of peptide libraries.
    Leinonen J; Wu P; Stenman UH
    Clin Chem; 2002 Dec; 48(12):2208-16. PubMed ID: 12446478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
    Kinoshita Y; Kuratsukuri K; Newman N; Rovito PM; Kaumaya PT; Wang CY; Haas GP
    Prostate Cancer Prostatic Dis; 2005; 8(4):359-63. PubMed ID: 16172607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
    Arlen PM; Gulley JL; Tsang KY; Schlom J
    Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
    Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY
    J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification of human prostatic-specific antigen (hPSA) from seminal plasma by immunoaffinity chromatography using a monoclonal antibody anti total PSA.
    Pérez L; Zulueta O; Melchor A; Hernández L; López R; Cazanave J; Béquer D
    Hybridoma (Larchmt); 2011 Jun; 30(3):247-51. PubMed ID: 21707359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.